Dean Lloyd Minor welcomes former FDA commissioner Dr. Scott Gottlieb to discuss the role of government agencies in improving public health and handling crises. During their conversation, they examine the influence of business, politics, and finance on science and medicine, how to strike a balance between innovation and regulation in the health market, and changes that would better prepare the U.S. for the next public health crisis. They also dive into the importance of active listening in leadership, being open to new organizational mindsets, and anticipating the range of reactions from businesses, communities, and individuals in times of uncertainty.
Meet Scott Gottlieb
A Pfizer Director since 2019, Dr. Scott Gottlieb serves as their Chair of the Regulatory and Compliance Committee and as a Member of their Science and Technology Committee.
Dr. Gottlieb was also the 23rd Commissioner of the U.S. FDA from 2017 to 2019 and is a Special Partner at New Enterprise Associates Inc.’s healthcare investment team.
Prior to serving as FDA Commissioner, Dr. Gottlieb held several roles in the public and private sector including Managing Director of T.R. Winston & Company from 2013 to 2017, the FDA’s Deputy Commissioner for Medical and Scientific Affairs from 2005 to 2007, and senior advisor to the FDA Commissioner from 2003 to 2004.
Dr. Gottlieb is a member of the National Academy of Medicine and is a Contributor to the financial news network, CNBC. He is a Director at Illumina, Inc., and at private healthcare data technology companies Aetion, Inc. and Tempus. He also serves as a Board Member of National Resilience Inc., and as a Scientific Advisory Board Member of CellCarta.